2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related

Interleukin Related

IL

Interleukin Related

Related Products

PDF 1.53 MB

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Interleukin Related Isoform Specific Products:

Interleukin Related Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W011978
    N-Acetyl-L-tryptophan
    		Inhibitor 99.38%
    N-Acetyl-L-tryptophan is an antagonist of the neurokinin-1 receptor (NK-1R), disrupting the binding of substance P (SP) to NK-1R. This action provides neuroprotective effects, improving memory deficits and motor impairments. N-Acetyl-L-tryptophan is also an inhibitor of cytochrome c (Cytochrome c), and it exerts antioxidant and anti-inflammatory effects by inhibiting the expression of IL-1β and the activation of caspase-1. N-Acetyl-L-tryptophan holds promise for research in neurodegenerative and inflammatory diseases.
    N-Acetyl-L-tryptophan
  • HY-N7674
    Angoline
    		99.67%
    Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.
    Angoline
  • HY-P99246
    Bermekimab
    		Inhibitor
    Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). Bermekimab prevents tumour-related inflammation.
    Bermekimab
  • HY-101259
    BMS-195614
    		Inhibitor 99.5%
    BMS-195614 (BMS 614) is an orally active neutral RARα-selective antagonist with a Ki of 2.5 nM. BMS-195614 restores the expression of Bcl2. BMS-195614 inhibits the transactivation of NF-κB, AP-1 and PPAR. BMS-195614 downregulates the expression of IL-6 and VEGF. BMS-195614 reduces blue light-induced phototoxicity and inhibits cell migration. BMS-195614 modulates inflammation and angiogenesis.
    BMS-195614
  • HY-B0633C
    Hyaluronic acid (Mw:1000-2000Da)
    		Inhibitor
    Hyaluronic acid (Mw:1000-2000Da) is a long-chain, unbranched polysaccharide with a molecular weight of 1000-2000 Dalton. Hyaluronic acid (Mw:1000-2000Da) regulates tissue homeostasis and stress resistance, exhibits a pro-inflammatory effect (while hyaluronic acid with high molecular weight exhibits an anti-inflammatory effect), and promotes angiogenesis and tissue remodeling. Hyaluronic acid (Mw:1000-2000Da) exhibits good biocompatible and biodegradable characteristics, that can be used in drug delivery systems and tissue engineering.
    Hyaluronic acid (Mw:1000-2000Da)
  • HY-B0240R
    Disulfiram (Standard)
    		Inhibitor
    Disulfiram (Standard) is the analytical standard of Disulfiram. This product is intended for research and analytical applications. Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram + Cu2+ increases intracellular ROS levels triggering apoptosis of ovarian cancer stem cells[1-6].
    Disulfiram (Standard)
  • HY-P99210
    Olokizumab
    		Inhibitor
    Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA).
    Olokizumab
  • HY-P9927A
    Secukinumab (Anti-Human IL-17A)
    		Antagonist
    Secukinumab (Anti-Human IL-17A) is a fully human anti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis.
    Secukinumab (Anti-Human IL-17A)
  • HY-P990217
    Anti-Mouse IL-23 p19 Antibody (G23-8)
    		Inhibitor
    Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-23 p19.
    Anti-Mouse IL-23 p19 Antibody (G23-8)
  • HY-125130
    Hesperetin 7-O-glucoside
    		Inhibitor 98.08%
    Hesperetin 7-O-glucoside is a typical flavonoid monoglucoside, which is an anti-inflammatory agent and an antihypertensive with orally active. Hesperetin 7-O-glucoside is a commonly used food adjuvant. Hesperetin 7-O-glucoside inhibits human intestinal maltase and human HMG-CoA reductase with Ki of 1.8 mM and 9.8 μM, respectively. Hesperetin 7-O-glucoside has antibacterial activity and can regulate intestinal flora and metabolic homeostasis in mice.
    Hesperetin 7-O-glucoside
  • HY-N2086
    Ethyl palmitate
    		Inhibitor 99.09%
    Ethyl palmitate (Ethyl hexadecanoate) is a CHIKV virus inhibitor with an EC50 value of 0.0068 μM. Ethyl palmitate can reduce levels of TNF-α, IL-6, and NF-κB in endotoxemic rats, showing anti-inflammatory activity.
    Ethyl palmitate
  • HY-15507
    VGX-1027
    		Inhibitor 99.76%
    VGX-1027 is an orally active isoxazole compound that exhibits various immunomodulatory properties. VGX-1027 targets macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, IL-10. VGX-1027 has antidiabetogenic effects by limiting cytokine-mediated immunoinflammatory events.
    VGX-1027
  • HY-101417
    Diethyl phosphate
    		Inhibitor ≥98.0%
    Diethylphosphate (Diethyl phosphoric acid) is an orally active organophosphorus pesticides metabolite. Diethylphosphate can interfere with thyroid hormone-related mechanisms and affect intestinal microbes in rats.
    Diethyl phosphate
  • HY-P99233
    Camidanlumab
    		Inhibitor 99.23%
    Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule ADCT-301 (Camidanlumab tesirine). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia.
    Camidanlumab
  • HY-P99752
    Nemvaleukin alfa
    		99.50%
    Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer.
    Nemvaleukin alfa
  • HY-111346
    1-Linoleoyl Glycerol
    		Inhibitor ≥98.0%
    1-Linoleoyl glycerol is a LpPLA2 inhibitor. 1-Linoleoyl glycerol acts as a precursor for synthesizing various functional lipids, such as phospholipids. 1-Linoleoyl glycerol mitigates inflammation induced by Apolipoprotein CIII (reduction of IL-6).
    1-Linoleoyl Glycerol
  • HY-162734
    BRD5075
    		Inhibitor 98.08%
    BRD5075 is a potent GPR65 activator. BRD5075 induces GPR65-dependent cAMP production. BRD5075 decreases the gene expression of IL-1, IL-2, TNF, and chemokine. BRD5075 has the potential for the research of multiple sclerosis and inflammatory bowel disease (IBD).
    BRD5075
  • HY-B1051
    Flumethasone
    		Modulator 99.83%
    Flumethasone (Flumetasone) is an orally active, high selective and potent glucocorticoid receptor (GR) agonist. Flumethasone activates GR to inhibit nuclear factor kappa B (NF-κB)-mediated pro-inflammatory cytokine production (TNF-α, IL-1β) and promotes anti-inflammatory gene expression (IL-10), while also regulating metabolic enzyme activity (tyrosine aminotransferase induction). Flumethasone is promising for research of inflammatory diseases, cancer, and endocrine regulation.
    Flumethasone
  • HY-114775
    RCGD423
    		Modulator 99.92%
    RCGD423 is a gp130 modulator, which prevents articular cartilage degeneration and promotes repair.
    RCGD423
  • HY-16785
    Veledimex
    		Activator 98.45%
    Veledimex (INXN-1001), a synthetic analog of the insect molting hormone ecdysone, is an orally active activator ligand for a proprietary gene therapy promoter system. Veledimex can be used to activate certain genes using the ecdysone receptor (EcR)-based inducible gene regulation system, the RheoSwitch Therapeutic System (RTS). Veledimex can cross blood-brain barrier (BBB) in both orthotopic GL-261 mice and cynomolgus monkeys.
    Veledimex
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Interleukin Related Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.